- Home
- ENS vs NAMS Comparison
ENS vs NAMS Comparison
Compare ENS & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENS
- NAMS
- Stock Information
- Founded
- ENS 1991
- NAMS 2019
- Country
- ENS United States
- NAMS Netherlands
- Employees
- ENS N/A
- NAMS N/A
- Industry
- ENS Industrial Machinery/Components
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- ENS Technology
- NAMS Health Care
- Exchange
- ENS Nasdaq
- NAMS Nasdaq
- Market Cap
- ENS 3.4B
- NAMS 3.1B
- IPO Year
- ENS N/A
- NAMS N/A
- Fundamental
- Price
- ENS $114.31
- NAMS $32.86
- Analyst Decision
- ENS Strong Buy
- NAMS Strong Buy
- Analyst Count
- ENS 2
- NAMS 9
- Target Price
- ENS $117.50
- NAMS $41.89
- AVG Volume (30 Days)
- ENS 342.8K
- NAMS 974.1K
- Earning Date
- ENS 11-05-2025
- NAMS 11-05-2025
- Dividend Yield
- ENS 0.93%
- NAMS N/A
- EPS Growth
- ENS 32.64
- NAMS N/A
- EPS
- ENS 8.77
- NAMS N/A
- Revenue
- ENS $3,657,687,000.00
- NAMS $64,006,000.00
- Revenue This Year
- ENS $2.83
- NAMS N/A
- Revenue Next Year
- ENS $3.01
- NAMS $1.67
- P/E Ratio
- ENS $12.90
- NAMS N/A
- Revenue Growth
- ENS 3.73
- NAMS 762.15
- 52 Week Low
- ENS $76.57
- NAMS $14.06
- 52 Week High
- ENS $117.94
- NAMS $34.62
- Technical
- Relative Strength Index (RSI)
- ENS 61.44
- NAMS 72.18
- Support Level
- ENS $108.19
- NAMS $27.15
- Resistance Level
- ENS $117.94
- NAMS $34.59
- Average True Range (ATR)
- ENS 2.44
- NAMS 1.47
- MACD
- ENS -0.22
- NAMS 0.50
- Stochastic Oscillator
- ENS 47.62
- NAMS 73.37
About ENS EnerSys
EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, and Specialty.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.